Calcineurin Inhibitor Sparing After Kidney Transplantation

Completed · Phase 1/Phase 2

Conditions studied: CNI Side Effects

In brief

Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant function in those who have had their transplants for many years. The introduction of new immunosuppression medications however, has provided the opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the kidney.

Key facts

Study ID

NCT01062555

Run by

University of Minnesota

People needed

527

Starts

2006-10-01

Expected to finish

2014-04-03

Last updated by the study team

2020-12-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney Transplant Recipients > 18 years old
• First or Second Kidney Transplant only

You may not qualify if…

• Kidney Transplant Recipients < 18 years old
• Kidney Transplant Recipients who have a history of > 2 kidney transplants
• Kidney Transplant Recipients with an already functioning non-renal transplant
• Kidney Transplant Recipients who receive another organ simultaneously at the same time of their kidney transplant (example: Kidney/pancreas, kidney/liver)
• Non-skin malignancy with 2 years previous to enrollment
• Donor Specific Antibodies to kidney donor

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.